PEPCID COMPLETE Drug Patent Profile
✉ Email this page to a colleague
When do Pepcid Complete patents expire, and when can generic versions of Pepcid Complete launch?
Pepcid Complete is a drug marketed by J And J Consumer Inc and is included in one NDA.
The generic ingredient in PEPCID COMPLETE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and eighty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PEPCID COMPLETE?
- What are the global sales for PEPCID COMPLETE?
- What is Average Wholesale Price for PEPCID COMPLETE?
Summary for PEPCID COMPLETE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 35 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PEPCID COMPLETE |
| What excipients (inactive ingredients) are in PEPCID COMPLETE? | PEPCID COMPLETE excipients list |
| DailyMed Link: | PEPCID COMPLETE at DailyMed |
Recent Clinical Trials for PEPCID COMPLETE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ohio State University Comprehensive Cancer Center | Phase 2/Phase 3 |
| United States Department of Defense | Phase 2 |
| Leidos Life Sciences | Phase 2 |
Pharmacology for PEPCID COMPLETE
| Drug Class | Histamine-2 Receptor Antagonist |
| Mechanism of Action | Histamine H2 Receptor Antagonists |
Paragraph IV (Patent) Challenges for PEPCID COMPLETE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| PEPCID COMPLETE | Chewable Tablets | calcium carbonate; famotidine; magnesium hydroxide | 800 mg/10 mg/ 165 mg (OTC) | 020958 | 1 | 2004-11-01 |
US Patents and Regulatory Information for PEPCID COMPLETE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | PEPCID COMPLETE | calcium carbonate; famotidine; magnesium hydroxide | TABLET, CHEWABLE;ORAL | 020958-001 | Oct 16, 2000 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEPCID COMPLETE
International Patents for PEPCID COMPLETE
See the table below for patents covering PEPCID COMPLETE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2079934 | ENROBAGES PERMETTANT DE MASQUER LE GOUT DE COMPRIMES PHARMACEUTIQUES MACHABLES (TASTE MASK COATINGS FOR PREPARING CHEWABLE PHARMACEUTICAL TABLETS) | ⤷ Sign Up |
| New Zealand | 238131 | CHEWABLE MEDICAMENT TABLETS FORMED FROM COMPRESSED COATED GRANULES; COATING IS A POLYMER BLEND MASKING TASTE AND PROVIDING SUSTAINED RELEASE | ⤷ Sign Up |
| Germany | 2951675 | ⤷ Sign Up | |
| Greece | 1002397 | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΕΧΕΙ ΜΙΑ ΓΟΥΑΝΙΔΙΝΟΘΕΙΑΖΟΛΙΚΗ ΕΝΩΣΗ ΚΑΙ ΑΝΤΙΟΞΙΝΑ. (Pharmaceutical composition containing a guanidinothiazole compound and antacids.) | ⤷ Sign Up |
| Lithuania | 2242 | ⤷ Sign Up | |
| Japan | S55118476 | NOVEL AMIDINE DERIVATIVE AND ITS PREPARATION | ⤷ Sign Up |
| South Africa | 8000970 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PEPCID COMPLETE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 300689 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 2957286 | LUC00094 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2957286 | 122018000145 | Germany | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 0933372 | PA2008006,C0933372 | Lithuania | ⤷ Sign Up | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| 2957286 | CA 2018 00043 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| 2365988 | LUC00061 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2365988 | CA 2018 00006 | Denmark | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
